A RANDOMIZED CONTROLLED TRIAL OF TAMOXIFEN VERSUS ETOPOSIDE FOR PATIENTS WITH FIRST RECURRENCE OF GLIOBLASTOMA MULTIFORME

Registry ID

IIT-0014

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

CROSS CANCER INSTITUTE - CANCER CARE ALBERTA

Start date

2025-09-24

Last update

2021-03-16

Conditions

• GLIOBLASTOMA

Related clinical trials

• A PHASE 1/2 STUDY TO ASSESS BDTX-1535, AN ORAL EGFR INHIBITOR, IN PATIENTS WITH GLIOBLASTOMA OR NON-SMALL CELL LUNG CANCER
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF OPTUNE® (TTFIELDS, 200 KHZ) CONCOMITANT WITH MAINTENANCE TEMOZOLOMIDE AND PEMBROLIZUMAB VERSUS OPTUNE® CONCOMITANT WITH MAINTENANCE TEMOZOLOMIDE AND PLACEBO FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA
• A PHASE 3, OPEN-LABEL, RANDOMIZED 2-ARM STUDY COMPARING THE CLINICAL EFFICACY AND SAFETY OF NIRAPARIB WITH TEMOZOLOMIDE IN ADULT PARTICIPANTS WITH NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA
• A RANDOMIZED PHASE II STUDY ON INTRA-ARTERIAL CARBOPLATIN COMBINED WITH CAELYX COMPARED TO INTRA-ARTERIAL CARBOPLATIN COMBINED WITH ETOPOSIDE PHOSPHATE FOR PROGRESSING GLIOBLASTOMA AT FIRST OR SECOND RELAPSE.
• BIOMARKER AND TUMOR CELL CULTURE-DRIVEN PILOT TRIAL FOR TREATMENT OF RECURRENT GLIOBLASTOMA
• AN OPEN-LABEL, MULTICENTER, PHASE I STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY CLINICAL ACTIVITY OF RO7428731 IN PARTICIPANTS WITH GLIOBLASTOMA EXPRESSING MUTANT EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III

View on source registry